Oculis Holding (OCS) has released an update.
Oculis Holding AG has reported positive outcomes from the Phase 2b RELIEF trial of their novel drug licaminlimab, showing significant improvements in the treatment of Dry Eye Disease (DED), particularly in patients with a specific genetic biomarker. The trial’s results demonstrated rapid and significant reduction in corneal inflammation and overall good tolerance of the medication, paving the way for Phase 3 development discussions with the FDA. The company’s approach signals a potential shift towards more personalized treatment strategies in ophthalmology.
For further insights into OCS stock, check out TipRanks’ Stock Analysis page.
